3 Stocks Pushing The Drugs Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

The Drugs industry as a whole closed the day down 0.3% versus the S&P 500, which was up 0.4%. Laggards within the Drugs industry included Reliv' International ( RELV), down 2.2%, ImmuCell ( ICCC), down 3.6%, Innocoll AG ADR ( INNL), down 7.9%, Cellectar Biosciences ( CLRB), down 1.7% and Ruthigen ( RTGN), down 2.1%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Cellectar Biosciences ( CLRB) is one of the companies that pushed the Drugs industry lower today. Cellectar Biosciences was down $0.04 (1.7%) to $2.55 on light volume. Throughout the day, 1,972 shares of Cellectar Biosciences exchanged hands as compared to its average daily volume of 18,600 shares. The stock ranged in price between $2.53-$2.60 after having opened the day at $2.60 as compared to the previous trading day's close of $2.59.

Cellectar Biosciences has a market cap of $19.0 million and is part of the health care sector. Shares are down 16.2% year-to-date as of the close of trading on Friday. Currently there is 1 analyst who rates Cellectar Biosciences a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Innocoll AG ADR ( INNL) was down $0.66 (7.9%) to $7.68 on light volume. Throughout the day, 300 shares of Innocoll AG ADR exchanged hands as compared to its average daily volume of 5,200 shares. The stock ranged in price between $7.68-$7.68 after having opened the day at $7.68 as compared to the previous trading day's close of $8.34.

Innocoll AG ADR has a market cap of $166.3 million and is part of the health care sector. Shares are up 41.5% year-to-date as of the close of trading on Friday. Currently there are 2 analysts who rate Innocoll AG ADR a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Reliv' International ( RELV) was another company that pushed the Drugs industry lower today. Reliv' International was down $0.02 (2.2%) to $1.10 on average volume. Throughout the day, 9,000 shares of Reliv' International exchanged hands as compared to its average daily volume of 9,400 shares. The stock ranged in price between $1.09-$1.13 after having opened the day at $1.13 as compared to the previous trading day's close of $1.13.

Reliv' International, Inc. develops, manufactures, and markets nutritional supplements that promote basic nutrition, weight loss, athletic performance, digestive health, women's health, anti-aging, and healthy energy. Reliv' International has a market cap of $14.2 million and is part of the health care sector. Shares are down 3.4% year-to-date as of the close of trading on Friday.

TheStreet Ratings rates Reliv' International as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, attractive valuation levels and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and a generally disappointing performance in the stock itself.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on RELV go as follows:

  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Personal Products industry. The net income increased by 98.6% when compared to the same quarter one year prior, rising from $0.50 million to $1.00 million.
  • RELV's debt-to-equity ratio is very low at 0.21 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.91 is somewhat weak and could be cause for future problems.
  • RELV's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 51.31%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Personal Products industry and the overall market, RELIV INTERNATIONAL INC's return on equity significantly trails that of both the industry average and the S&P 500.

You can view the full analysis from the report here: Reliv' International Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

U.S. Equities Rise as Microsoft Gains Offset GE Weakness

U.S. Equities Rise as Microsoft Gains Offset GE Weakness

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

NYSE Trader Expects Blowout Earnings From Alphabet, Amazon and Facebook

NYSE Trader Expects Blowout Earnings From Alphabet, Amazon and Facebook

NYSE Trader: I Think Oil Is Fairly Priced

NYSE Trader: I Think Oil Is Fairly Priced

NYSE Trader: For Long-Term Investors General Electric Is a Buy

NYSE Trader: For Long-Term Investors General Electric Is a Buy